Dr. Htut on CAR T-Cell Therapy in Patients With Multiple Myeloma

Video

Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.

Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.

City of Hope now has 2 different protocols for the use of CAR T-cell therapy in patients with multiple myeloma. First is the BCMA-targeted therapy protocol from Juno therapeutics. The second protocol is high-affinity T-cell receptor targeting NY-ESO-1/HLA-A. Both are active and currently enrolling patients. Physicians at City of Hope also plan to have a homegrown CAR T-cell therapy targeting CS1. The study will be led by Htut, the principal investigator, pending FDA approval.

There are other potential targets including CD44v6, CD8, and CD138. Physicians are also looking to combine a T cell that can target CS1 as well as BCMA.

Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
© 2024 MJH Life Sciences

All rights reserved.